RxDoctor Payments Data

Brian Bhagat, MD

Internal Medicine · Flint, MINPI 1396746582

Payments from drug & device makers

$6,311in general payments, 2019–2025

Across 355 payments — averaging $17.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$1K
  • Novo Nordisk$863
  • Amgen$652
  • AbbVie$549
  • AstraZeneca$469
  • GSK$306
  • plus $2K from 33 others

What the payments were for

  • Food & beverage$6,306100%
  • Education$40%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,311 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$228,889
Medicare patients
410
Services billed
2,631

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban453$537,978
MounjaroTirzepatide207$284,952
TrulicityDulaglutide91$184,770
XareltoRivaroxaban113$155,109
JanuviaSitagliptin Phosphate106$133,849
JardianceEmpagliflozin81$112,202
OzempicSemaglutide70$83,603
RybelsusSemaglutide30$67,552
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$58,532
ForteoTeriparatide13$53,873
Repatha SureclickEvolocumab48$53,745
EntrestoSacubitril/Valsartan30$49,444
FarxigaDapagliflozin Propanediol40$49,218
ProliaDenosumab28$46,594
KerendiaFinerenone28$41,290

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$38$576,011507 claims
Lilly USA, LLCMounjaro, Trulicity, Forteo$134$523,594311 claims
Johnson & JohnsonXarelto$28$155,109113 claims
Novo NordiskOzempic, Rybelsus$863$151,155100 claims
Boehringer IngelheimJardiance, Tradjenta$82$146,245115 claims
AstraZenecaFarxiga, Breztri Aerosphere$469$62,99355 claims
GSKTrelegy Ellipta$306$58,53253 claims
AbbVieLinzess, Vraylar$549$58,51763 claims
NovartisEntresto$141$49,44430 claims
AmgenProlia$652$46,59428 claims
BayerKerendia$1,352$41,29028 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Flint

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →